Innoviva, Inc. (INVA) — closed signal from March 9, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 7, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published March 9, 2026
Recent company news makes the stock less risky on the downside even though the price pattern has not fully turned positive. A higher analyst target, a new buyback, and a big cash balance make it easier for the stock to be revalued if investors start liking the commercial biotech story. Best bought in smaller chunks.
Primary drivers
- New buyback reduces downside risk and shows discipline
- Big cash balance gives the company flexibility
- Analyst raising target improves short-term outlook
- Revenue from products and royalties spreads risk
How it played out
INVA: target missed after an 11.6% peak gain
Lyra published INVA at $21.92 on March 9, 2026, with 12% expected growth over a short-term window. The thesis pointed to a new buyback, a big cash balance, a higher analyst target, and revenue from products and royalties that spread risk.
Inside the window, INVA rose to $24.45 on April 20, 2026, for an 11.6% peak gain. The target was $24.54. It never got there. The stock ended the window at $22.52 on June 7, 2026. The thesis mostly played out on price, but it missed the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.